TICKERNERD
Menu
BRVEHealthcare · Biotechnology

BRVE Stock Forecast: Braveheart Bio, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$29
+9.99% on the day

The 5 Wall Street analysts covering Braveheart Bio, Inc. hold a median 12-month price target of $47 — +58.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 7 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
1 / 100
Median analyst target
$47
Analysts covering
5
Total return, dividends reinvested
1W
+15.3%
1M
−2.0%
From high
−2.0%
From low
+17.6%
$25
$30
Range since 6 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

BRVE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Braveheart Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
37
Revisions
35
Value
15
Issuance
11
Growth
8
Accruals
8
Momentum
5
Quality
4
Volatility
4

Size (37): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BRVE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BRVE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Aug 2026Adjusted close, US dollars
$25$30$35$40$45$50Aug 26Aug 26Aug 26Aug 26Sep 26BRVEHigh $48Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $40Median $47High $48

The green dot is the last close — the median target sits +58.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Aug 2026Cantor FitzgeraldInitiatesOverweight$40
31 Aug 2026Goldman SachsInitiatesBuy$48
31 Aug 2026JefferiesInitiatesBuy$48
31 Aug 2026StifelInitiatesBuy$45
31 Aug 2026TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRVE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BRVE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

BRVE vs S&P 500, last 12 monthsTotal return, rebased to 100
9095100Aug 26Aug 26Aug 26Aug 26Sep 26BRVES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BRVE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Braveheart Bio, Inc. (BRVE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
15.3×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
100.3%

Higher than 96% of US stocks

Return on assets
−73.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Braveheart Bio, Inc. (BRVE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Braveheart Bio, Inc. has a market value of $1.9B and an enterprise value of $885.1M.

  • Shares outstanding: 70.7M.

  • forward P/E: −13.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Braveheart Bio, Inc. employs 30 people.

market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

BRVE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BRVEBraveheart Bio, Inc.$1.9B
1
RXRXRecursion Pharmaceuticals, Inc.$1.9B
43
XNCRXencor, Inc.$1.9B
81
MRVIMaravai Lifesciences Holdings, Inc.$1.9B
91
VIRVir Biotechnology, Inc.$1.9B
94
STOKStoke Therapeutics, Inc.$1.9B
55
AGIOAgios Pharmaceuticals, Inc.$1.9B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Braveheart Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BRVE news & analysis

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 8 Sept 2026positive

Braveheart Bio reported unaudited financial results for the second quarter ended June 30, 2026, and announced the initiation of the Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The company reported cash and cash equivalents of $122.8 million as of June 30, 2026, or $527.3 million after giving effect to its initial public offering, which is expected to support advancement of BHB-1893 through late-stage clinical development.

Why it matters — The Phase 3 trial initiation and substantial post-IPO cash position signal progress in advancing BHB-1893, its lead candidate, toward late-stage development in hypertrophic cardiomyopathy.

Braveheart Bio to Participate in Cantor Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Braveheart Bio, Inc. announced it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. The clinical-stage biopharmaceutical company develops next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases.

Why it matters — A BRVE watcher would care because conference participation offers the company a platform to present its developments to the healthcare investment community.

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The Motley Fool · 10 Aug 2026positive

Braveheart Bio's CFO purchased 27,777 shares for approximately $500,000 on August 7, 2026, boosting total equity by 5% and raising his ownership stake to 0.87%.

Why it matters — An insider's significant share purchase can signal confidence in the company's prospects, making it noteworthy for shareholders and prospective investors monitoring BRVE.

FAQ

Frequently asked questions about BRVE stock

What is the BRVE stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Braveheart Bio, Inc. have a median 12-month price target of $47, with estimates ranging from $40 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BRVE stock a buy right now?

Of the 5 analysts covering Braveheart Bio, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Braveheart Bio, Inc. 1 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BRVE?

As at 7 Sept 2026, Braveheart Bio, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (37 of 100).

Will BRVE stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +58.1% from the last close, and Ticker Nerd's factor model ranks Braveheart Bio, Inc. 1 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BRVE stock forecast for 2030?

No analyst covering Braveheart Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRVE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $48 over the next 12 months.

What does Braveheart Bio, Inc. do?

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases.

What is the latest news on BRVE?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update". Braveheart Bio reported unaudited financial results for the second quarter ended June 30, 2026, and announced the initiation of the Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The company reported cash and cash equivalents of $122.8 million as of June 30, 2026, or $527.3 million after giving effect to its initial public offering, which is expected to support advancement of BHB-1893 through late-stage clinical development.

Company

About Braveheart Bio, Inc.

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead program centers on BHB-1893, an oral small-molecule cardiac myosin inhibitor designed for both obstructive and non-obstructive forms of the disease. The company’s work is aimed at advancing treatment options for patients with limited therapeutic choices, with a focus on cardiovascular medicine and heart muscle disorders. Braveheart Bio operates as a drug-development company, supporting research and clinical development across its current pipeline rather than commercial product sales. Headquartered in San Francisco, California, Braveheart Bio was incorporated in 2024 and is positioned within the biotechnology sector as a developer of specialized cardiovascular therapies.

CEO Dr. Travis Murdoch B.S., M.D., M.Sc. · 30 employees · United States · https://www.braveheart.bio